
Benzinga Pro data, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 sales of $1.82 million. Earnings fell to a loss of $42.87 million, resulting in a 22.1% decrease from last quarter. In Q3, Rhythm Pharmaceuticals brought in $1.03 million in sales but lost $35.11 million in earnings.